glp-1 with cv benefit Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community GLP-1 receptor agonist therapy for

Hypertension (high blood pressure) Dyslipidemia (high cholesterol) Coronary artery disease Heart failure Obstructive sleep apnea (confirmed by sleep study) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Intracerebral hemorrhage (stroke) Gastroesophageal reflux disease Osteoarthritis Obesity hypoventilation syndrome/Pickwickian syndrome (confirmed by sleep study) Metabolic syndrome What is the timeline to participate in the GLP-1 Pilot Program and receive Approval by Exception

Abbreviations GLP-1 RAs: Glucagon-like peptide-1 receptor agonists T2DM: Type 2 diabetes mellitus COPD: Chronic obstructive pulmonary disease BMI: Body mass index HbA1c: Glycated hemoglobin RR: Relative risk CI: Confidence interval RCT: Randomized controlled trial CVOT: Cardiovascular outcome trial PRISMA: Preferred reporting items for systematic reviews and meta-analyses References Zar HJ, Ferkol TW

Research Compound Disclaimer: IGF-1 LR3 is not approved by the FDA for human use and is available solely as a research chemical

At Onus iV, your IV infusion is administered by experienced professionals under ER protocols, as all staff are required to have a minimum of 2 years ER/ICU experience

Severe folate deficiency causes secondary depletion of choline and phosphocholine in rat liver